Abstract
A global breakthrough in oral chelation therapy with the a-ketohydroxypyridine chelating drug l,2-dimethyl-3-hydroxypyrid-4-one (LI, INN/BAN: Deferiprone) (Kontoghiorghes 1982) in iron and aluminium overloaded patients has recently been achieved. Since the initiation of clinical trials with LI in 1987 and prior to its recent registration in India, over 800 patients with ten different conditions in 16 countries have received it, in some cases daily for over 6 years. The major toxic side effects, which all appear to be reversible, include agranulocytosis, musculoskeletal and joint pains, zinc deficiency and gastric intolerance. Oral LI appears to be as effective as subcutaneous desferoxamine (DF) in iron and aluminium removal and has low toxicity. Other α-ketohydroxypyridines are also currently being developed.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Agarwal MB, Gupta SS, Viswanathan C, et al (1992a) Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassaemia. Indian trial. Drugs Today 28 (Suppl A): 107 – 114
Anderson WF, Hiller MC (eds) (1975) Development of iron chelators for clinical use. National Institute of Health. Bethesda USA: 1 – 277
Brock J, Liceaga J, Kontoghiorghes GJ (1988) The effect of synthetic iron chelators on bacterial growth in human serum. FEMS Microbiol Immunol 47: 55 – 60
Carnelli V, Spadaro C, Stefano V, Battaglioli M, Fossati G, Perri M (1992) LI efficacy and toxicity in poorly compliant and for refractory to desferrioxamine thalassaemia patients: Interim report. Drugs Today. 28 (Suppl A): 119 – 121
Cunningham JM, Hunter A, Francis GE, Kontoghiorghes GJ, Hoffbrand AV (1991) Differential cytotoxicity of oral iron chelators and desferrioxamine to human bone marrow haemopoietic progenitor cells in vitro. Brit J Haematol 77 (suppl 1): 381
Donfrancesco A, Deb G, Dominici C, Castello MA, Helson L (1990) Effects of a single course of deferoxamine in Neuroblastoma patients. Cancer Res 50: 4929–4930
Edwardson JA, Ferrier IN, McArthur FK et al (1992) Alzheimer’s disease and the aluminium hypothesis. In: Aluminium in Chemistry, Biology and Medicine. Nicolini, Zatta PF, Corain B (eds). Raven Press, New York 1: 85 – 96
Estrow ZA, Tawa XH, Dube ID et al (1987) In vitro and in vivo effects of deferoxamine in neonatal acute leukaemia. Blood 69: 757 – 761
Eybl V, Svihovcov P, Kontensky J, Kontoghiorghes GJ (1992) Interaction of LI, L1NA11 and deferoxamine with Gallium in vivo. Drugs Today 28 (Suppl A): 173 – 175
Ganeshaguru K, Lally KM, Piga A, Hoffbrand AV, Kontoghiorghes GJ (1992) Cytotoxic mechanisms of iron chelators. Drugs Today 28 (Suppl A): 29 – 34
Giordano N, Sancasciani S, Borghi C, Fiorauenti A, Marcolongo P (1986) Antianemic and potential anti-inflammatory activity of desferrioxamine: Possible usefulness in rheumatoid arthritis. Clin Exp Rheumatol 4: 25 – 29
Goudsmit R, Kersten MJ (1992) Long term treatment of transfusion hemosiderosis with the oral iron chelator LI. Drugs Today 28 (Suppl A): 133 – 135
Halliwell B, Gutteridge JMC, Cross CE (1992). Free radicals, antioxidants and human disease: Where are we now? J Lab Clin Med 119: 598 – 620
Heppner DG, Hallaway PE, Kontoghiorghes GJ, Eaton JW (1988) Antimalarial properties of orally active iron chelators. Blood 72: 358 – 361
Jaeger M, Aul C, Sohngen D, Germing U, Schneider W (1992) Iron overload in polytransfused patients with MDS; Use of LI for oral iron chelation. Drugs Today 28 (Suppl A): 143 – 147
Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, Dandona P (1988) The iron chelators desferrioxamine and l-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacylin synthesis in vitro. Biochem J 254: 239 – 244
Kontoghiorghes GJ (1982) The design of orally active iron chelators for the treatment of thalassaemia. PhD thesis, University of Essex, Colchester UK. British Library Microfilm No D66194 /86
Kontoghiorghes GJ (1986) Orally active a-ketohydroxypyridine iron chelators: studies in mice. Mol Pharmacol 30: 670 – 673
Kontoghiorghes GJ (1990a) Design, properties and effective use of the oral chelator LI and other a-ketohydroxypyridines in the treatment of transfusional iron overload in thalassaemia Ann NY Acad Sci 612: 339 – 350
Kontoghiorghes GJ (1990 b) Chelators affecting iron absorption in mice. Arzneim.Forsch/Drug Res. 40:1332–1335
Kontoghiorghes GJ (1992) Advances in oral iron chelation in man. Intern J Haematol 55: 27 – 38
Kontoghiorghes GJ (1993) Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. Indian J Paediatr 60: 485 – 507
Kontoghiorghes GJ (1993) Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. Indian J Paediatr 60: 485 – 507
Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV et al (1987a) Effective chelation of iron in ß-thalassaemia with the oral chelator l,2-dimethyl-3-hydroxypyrimid-4-one. Br Med J 295: 1509 – 1512
Kontoghiorghes GJ, Aldouri MA, Sheppard LN, Hoffbrand AV (1987b) l,2-Dimethyl-3- hydroxypyrid-4-one, an orally active chelator for the treatment of transfusional iron overload. Lancet i: 1294–1295
Kontoghiorghes GJ, Barr J, Baillot R (1992) Aluminium mobilisation in renal dialysis patients using the oral chelator l,2„dimethyl„3„hydroxypyrid„4„one (LI). Drugs Today 28 (Suppl A): 183 – 187
Kontoghiorghes GJ, Barr J, Baillot R (1994) Studies of aluminium mobilisation in renal dialysis patients using the oral chelator l,2-dimethyl-3-hydroxypyrid-4-one. Arzneim Forsch/Drug Res 44: 522 – 526
Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L. (1993) Selection of a newgeneration of new orally active a-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload. Amer J Haematol 42: 440 – 444
Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV et al (1990c) Long term trial with the oral iron chelator l,2-dimethyl-3-hydroxypyrid-4-one (L1). (1) Iron chelation and metabolic studies. Br. J Haematol 76: 295 – 300
Kontoghiorghes GJ, Bartlett AN, Sheppard L, Barr J, Nortey P (1995) Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes. Arzneim Forsch/Drug Res 45: 65 – 69
Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L (1990 b) Pharmacokinetic studies in humans with the oral iron chelator l,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharm Ther 48:255–261
Kontoghiorghes GJ, Sheppard LN (1987) Simple synthesis of the potent iron chelators 1- hydroxy-2-methylpyrid-4-ones. Inorg Chim Acta 136: L11 – L12
Kontoghiorghes GJ and Sheppard LN (1989) Process for producing pyrid-4-ones. European Patent Application No: 0335745
Kontoghiorghes GJ, Sheppard LN, Hoffbrand AV, Bartlett AN, Barr J (1990a) l-Ethyl-2- methyl-3-hydroxypyrid-4-one (LINEt) A new orally effective iron chelator for the treatment of transfusional iron overload. Blood 76:66a
Kontoghiorghes GJ, Weinberg ED (1995) Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches. Blood Rev 9: 33 – 45
Korkina LG, Afanas’ev IB, Deeva IB et al (1992) Free radical status of blood of patients with iron overload: the effect of chelating treatment. Drugs Today 28 (Suppl A): 137 – 141
Lin JY, Ling KH (1973) Studies on free amino acids in the seeds of Leucaena Glauca Benth:H[, biological study of mimosine. J Formosan Med Assoc 60: 657 – 664
Martell AE, Anderson WF, Badman DG (eds) (1980) Development of iron chelators for clinical use. Amsterdam: Elsevier: 1 – 311
Molenda J J, Jones MM, Basinger MA (1994) Enchancement of iron excretion via monoanionic 3-hydroxypyrid-4-ones. J Med Chem 37: 93 – 98
Motekaitis RJ, Martell AE (1991) Stabilities of the iron (III) chelates of l,2-dimethyl-3- hydroxy-4-pyridinone and related ligands. Inorg Chim Acta 183: 71 – 80
Nielsen P, Frtjes M, Drescow B, Fischer R, Engelhardt R, Heinrich HC (1992) The iron- decorporating effect of LI in normal and TMH-ferrocene iron loaded rats and in one patient with post-transfusional siderosis as judged by 59Fe-labelling technique. Drugs Today 28 (Suppl A): 45 – 53
Olivieri NF, Brittenham GM, Matsui D et al (1995) Iron-chelation therapy with oral deferiprone in patients with thalassaemia major. N Engl J Med 332: 918 – 922
Pippard MJ, Jackson MJ, Hoffman K, Petrou M, Modell CB (1986) Iron chelation using subcutaneous infusion of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol 36: 466 – 472
Politis C, Vrettou H, Fragatou S et al (1993) Reactions to subcutaneous application of iron chelation therapy with desferoxamine. An urgent need for oral chelators. Abstracts, 4th ICOC Limassol, Cyprus 4
Porter JB, Weir TB, Marshall L et al (1993) Clinical trials with the orally active hydroxypyridone CP94: Implications for future strategies in iron chelation therapy. Abstracts, 4th ICOC Limassol, Cyprus 18
Sheppard L, Kontoghiorghes GJ (1992) Synthesis and metabolism of LI and other novel alpha-ketohydroxypyridine iron chelators and their metal complexes. Drugs Today. 28 (Suppl A): 3 – 10
Sheppard LN and Kontoghiorghes GJ (1993) Competition between deferiprone, desferoxamine and other chelators for iron and the eflFect of other metals. Arzneim. Forsch/DrugRes 43: 659 – 663
Taylor D, Kontoghiorghes GJ (1986) Mobilisation of plutonium and iron from transferrin and ferritin by a-oxohydroxypyridine chelators. Inorg Chim Acta 125: L35 – L38
Tsai WC, Ling KH (1971) Effect of metals on the absorption and excretion of mimosine and 3,4-dihydroxypyridine in rat in vivo. J Formosan Med Assoc 73: 543 – 549
Tsai WC, Ling KH (1973) Study of the stability constant of some metal ion chelates of mimosine and 3,4-dihydroxypyridine. J Chin Biol Soc 2: 70 – 86
Tondury P, Kontoghiorghes GJ, Ridolfi„Luthy R et al (1990) LI (l,2-dimethyl-3- hydroxypyrid-4-one) for oral iron chelation in patients with ß-thalassaemia major. Br J Haematol 76: 550 – 553
Vreugdenhil G, Kontogfriorghes GJ, Van Eijk HG, Swaak AJG (1991) Impaired erythropoietin responsiveness to the anemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2- dimethyl-3- hydroxypyrid-4-one. Clin Exp Rheumatol 9: 35 – 40
Weinberg ED (1984) Iron withholding: a defense against infection and neoplasia. Physiol. Revs 64: 65 – 102
World Health Organisation Bulletin (1983) Community control of hereditary anaemias 61: 63 – 80
Zurlo MG, De Stefano P, Borgna-Pignatti C et al (1989) Survival and causes of death in thalassaemia major. Lancet ii: 27 – 29
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kontoghiorghes, G.J. (1996). Chemical, Pharmacological, Toxicological and Therapeutic Advances of Deferiprone (L1) and Other Iron and Aluminium Chelators. In: Seiler, J.P., Kroftová, O., Eybl, V. (eds) Toxicology - From Cells to Man. Archives of Toxicology, vol 18. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61105-6_21
Download citation
DOI: https://doi.org/10.1007/978-3-642-61105-6_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64696-6
Online ISBN: 978-3-642-61105-6
eBook Packages: Springer Book Archive